上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,100000+投资菁英共同关注今日,默沙东出了一个booming news:在研口服PCSK9抑制剂enlicitide decanoate(MK-0616)在三项3期临床试验中的前两项取得积极结果,也就是说,enlicitide decanoate有望成为获美国FDA批准的首款口服PCSK9抑制剂。降脂这些年来是个老生常谈的话题,这无可厚非。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.